Dr. Crowe is Director of the Vanderbilt Vaccine Center and Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center. He is a board-certified pediatric infectious diseases physician and viral immunology researcher. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. He is an elected member of the U.S. National Academy of Medicine and U.S. National Academy of Inventors, is an ISI Highly Cited Researcher and has been the recipient of numerous investigator awards. Many vaccine candidates and human monoclonal antibodies developed during his team’s research have been tested in Phase I-III clinical trials in humans, including tixagevimab + cilgavimab (Evusheld) that obtained emergency approval for preventing COVID-19.